Jeffry Katz, MD
Gastroenterology · Cleveland, OHNPI 1730109497
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (54.1%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by Boehringer Ingelheim at 57.4% of the total. Reporting peaked in 2019 at $5,544 and has fallen 81.7% since, to $1,016 in 2025.
Across 209 payments — averaging $40.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$5K
- AbbVie$1K
- Pfizer$911
- Johnson & Johnson$643
- Takeda Pharmaceuticals U.S.A., Inc.$408
- UCB, Inc.$234
- plus $261 from 10 others
Across 89 payments — averaging $6679.14 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$396K
- Janssen Research & Development, LLC$133K
- Boehringer Ingelheim$62K
- Boehringer Ingelheim RCV GmbH & Co KG$3K
- Bristol Myers Squibb$800
What the payments were for
- Consulting fees$4,63554%
- Travel & lodging$1402%
- Food & beverage$3,77444%
- Education$160%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 6 | $4,920 |
| AbbVie | 74 | $1,189 |
| Pfizer | 49 | $911 |
| Johnson & Johnson | 27 | $643 |
| Takeda Pharmaceuticals U.S.A., Inc. | 19 | $408 |
| UCB, Inc. | 19 | $234 |
| Nestle Healthcare Nutrition Inc. | 3 | $57 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $29 |
| Ferring Pharmaceuticals Inc. | 2 | $27 |
| Shire North American Group Inc | 2 | $26 |
| Organon | 1 | $24 |
| Amgen | 1 | $23 |
| Ironwood Pharmaceuticals, Inc | 1 | $21 |
| Celltrion USA Inc. | 1 | $19 |
| Lilly USA, LLC | 1 | $18 |
| Intercept Pharmaceuticals, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tremfya$123
How this compares
$8,565 in reported general payments places this provider in the 75th percentile of 657 gastroenterology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 80 | $2,148,013 |
| Humira(Cf) PenAdalimumab | 92 | $1,042,951 |
| RinvoqUpadacitinib | 67 | $644,029 |
| Xeljanz XrTofacitinib Citrate | 16 | $92,841 |
| Mesalamine | 50 | $23,715 |
| CreonLipase/Protease/Amylase | 13 | $20,579 |
| LinzessLinaclotide | 13 | $6,729 |
| Balsalazide Disodium | 27 | $6,455 |
| LoperamideLoperamide Hcl | 64 | $3,671 |
| Sulfasalazine DrSulfasalazine | 38 | $3,134 |
| Mercaptopurine | 27 | $2,837 |
| Sulfasalazine | 45 | $2,705 |
| Budesonide EcBudesonide | 11 | $2,666 |
| Azathioprine | 52 | $2,516 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 42 | $2,381 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $643 | $2,148,01380 claims |
| AbbVieRinvoq, Creon, Linzess | $1,189 | $671,33893 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 657 gastroenterology providers in Ohio.
Other gastroenterology in Cleveland
- Pierre GholamCleveland$1.6M
- Florian RiederCleveland$396K
- Stanley CohenCleveland$338K
- Taha QaziCleveland$307K
- Vu NguyenCleveland$145K
- Benjamin CohenCleveland$144K
- Imad AsaadCleveland$141K
- Ronnie FassCleveland$123K
- Amit BhattCleveland$118K
- Anjana PillaiCleveland$115K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.